G

Glenmark Life Sciences Ltd
NSE:GLS

Watchlist Manager
Glenmark Life Sciences Ltd
NSE:GLS
Watchlist
Price: 1 045.65 INR -3.19% Market Closed
Market Cap: 128.1B INR
Have any thoughts about
Glenmark Life Sciences Ltd?
Write Note

Glenmark Life Sciences Ltd
Note Receivable

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Glenmark Life Sciences Ltd
Note Receivable Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Note Receivable CAGR 3Y CAGR 5Y CAGR 10Y
G
Glenmark Life Sciences Ltd
NSE:GLS
Note Receivable
â‚ą122.6m
CAGR 3-Years
120%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
Note Receivable
â‚ą3.7B
CAGR 3-Years
9%
CAGR 5-Years
1%
CAGR 10-Years
N/A
Cipla Ltd
NSE:CIPLA
Note Receivable
â‚ą3.3B
CAGR 3-Years
1 392%
CAGR 5-Years
45%
CAGR 10-Years
0%
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
Note Receivable
â‚ą10.9B
CAGR 3-Years
-35%
CAGR 5-Years
-18%
CAGR 10-Years
-2%
T
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
Note Receivable
â‚ą2.3B
CAGR 3-Years
87%
CAGR 5-Years
18%
CAGR 10-Years
7%
M
Mankind Pharma Ltd
NSE:MANKIND
Note Receivable
â‚ą1.5B
CAGR 3-Years
0%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Glenmark Life Sciences Ltd
Glance View

Market Cap
128.1B INR
Industry
Pharmaceuticals

Glenmark Life Sciences Ltd. engages in the development and manufacture of non-commoditized active pharmaceutical ingredients. The company is headquartered in Solapur, Maharashtra. The company went IPO on 2021-08-06. The Company’s product portfolio comprises of various therapeutic segments, which include cardiovascular (CVS) disease, central nervous system (CNS) disorders, diabetes, gastrointestinal health, oncology, pain management and anti-infectives. Its products include Adapalene, Alogliptin Benzoate, Amiodarone HCl, Esomeprazole Sodium, Eszopiclone, Etoricoxib, Omeprazole, Oxcarbazepine, Zolpidem Tartrate, Zonisamide and Voriconazole. The Company’s products also include Vildagliptin, Aprepitant, Bosentan, Cilostazol, Deferasirox, Fluconazole, Ivacaftor, Pirfenidone, Riluzole, Sucralfate, Ticagrelor, Telmisartan and Umifenovir. The Company’s research and development facilities are located at Mahape, Ankleshwar and Dahej in India and manufacturing facilities are located at Ankleshwar, Dahej, Mohol and Kurkumbh.

GLS Intrinsic Value
715.71 INR
Overvaluation 32%
Intrinsic Value
Price
G

See Also

What is Glenmark Life Sciences Ltd's Note Receivable?
Note Receivable
122.6m INR

Based on the financial report for Mar 31, 2024, Glenmark Life Sciences Ltd's Note Receivable amounts to 122.6m INR.

What is Glenmark Life Sciences Ltd's Note Receivable growth rate?
Note Receivable CAGR 3Y
120%

Over the last year, the Note Receivable growth was 864%. The average annual Note Receivable growth rates for Glenmark Life Sciences Ltd have been 120% over the past three years .

Back to Top